115 related articles for article (PubMed ID: 26146802)
1. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era.
Mussetti A; Devlin SM; Castro-Malaspina HR; Barker JN; Giralt SA; Zelenetz AD; Sauter CS; Perales MA
Bone Marrow Transplant; 2015 Oct; 50(10):1293-1298. PubMed ID: 26146802
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation and CAR-T in B-cell Non-Hodgkin Lymphoma: a two-center experience and review of the literature.
Mercadal S; Mussetti A; Lee CJ; Arevalo C; Odstrcil SM; Peña E; Sureda A; Couriel DR
Ann Hematol; 2024 May; 103(5):1717-1727. PubMed ID: 38429536
[TBL] [Abstract][Full Text] [Related]
3. [The present and future of allogeneic hematopoietic stem cell transplantation for mantle cell lymphoma].
Liu Y; Huang XJ; Mo XD
Zhonghua Nei Ke Za Zhi; 2024 May; 63(5):512-516. PubMed ID: 38715492
[TBL] [Abstract][Full Text] [Related]
4. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Vaughn JE; Sorror ML; Storer BE; Chauncey TR; Pulsipher MA; Maziarz RT; Maris MB; Hari P; Laport GG; Franke GN; Agura ED; Langston AA; Rezvani AR; Storb R; Sandmaier BM; Maloney DG
Cancer; 2015 Oct; 121(20):3709-16. PubMed ID: 26207349
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.
Rezvani AR; Kanate AS; Efron B; Chhabra S; Kohrt HE; Shizuru JA; Laport GG; Miklos DB; Benjamin JE; Johnston LJ; Arai S; Weng WK; Negrin RS; Strober S; Lowsky R
Bone Marrow Transplant; 2015 Oct; 50(10):1286-92. PubMed ID: 26146806
[TBL] [Abstract][Full Text] [Related]
6. CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.
Tamari R; Chung SS; Papadopoulos EB; Jakubowski AA; Hilden P; Devlin SM; Goldberg JD; Perales MA; Ponce DM; Sauter CS; Maloy MA; Herman DY; Klimek V; Young JW; O'Reilly RJ; Giralt SA; Castro-Malaspina H
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2106-2114. PubMed ID: 26187863
[TBL] [Abstract][Full Text] [Related]
7. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.
Engelhardt M; Ihorst G; Landgren O; Pantic M; Reinhardt H; Waldschmidt J; May AM; Schumacher M; Kleber M; Wäsch R
Haematologica; 2015 Oct; 100(10):1340-9. PubMed ID: 26160877
[TBL] [Abstract][Full Text] [Related]
8. A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.
Tucker DL; Rule SA
Ther Clin Risk Manag; 2015; 11():979-90. PubMed ID: 26150724
[TBL] [Abstract][Full Text] [Related]
9. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.
Satlin MJ; Vardhana S; Soave R; Shore TB; Mark TM; Jacobs SE; Walsh TJ; Gergis U
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1808-14. PubMed ID: 26150022
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.
Karp Leaf R; Cho HJ; Avigan D
Curr Hematol Malig Rep; 2015 Dec; 10(4):395-404. PubMed ID: 26338470
[TBL] [Abstract][Full Text] [Related]
11. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.
Jiang H; Acharya C; An G; Zhong M; Feng X; Wang L; Dasilva N; Song Z; Yang G; Adrian F; Qiu L; Richardson P; Munshi NC; Tai YT; Anderson KC
Leukemia; 2016 Feb; 30(2):399-408. PubMed ID: 26338273
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
[TBL] [Abstract][Full Text] [Related]
13. Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.
Damaj G; Ivanoff S; Coso D; Ysaebert L; Choquet S; Houillier C; Parcelier A; Abarah W; Marjanovic Z; Gressin R; Garidi R; Diouf M; Gac AC; Dupuis J; Troussard X; Morschhauseur F; Ghesquières H; Soussain C;
Haematologica; 2015 Sep; 100(9):1199-206. PubMed ID: 26185174
[TBL] [Abstract][Full Text] [Related]
14. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
15. Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.
Roy A; Kish JK; Bloudek L; Siegel DS; Jagannath S; Globe D; Kuriakose ET; Migliaccio-Walle K
Am Health Drug Benefits; 2015 Jun; 8(4):204-15. PubMed ID: 26157542
[TBL] [Abstract][Full Text] [Related]
16. Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab.
Law JY; Kim DW; Sturgis A; Naina HV
Clin Med Insights Oncol; 2015; 9():61-3. PubMed ID: 26157340
[TBL] [Abstract][Full Text] [Related]
17. Time, timing, and the treatment of diffuse large B-cell lymphoma.
Gerds AT; Sekeres MA
Leuk Lymphoma; 2016 Feb; 57(2):247-248. PubMed ID: 26155827
[No Abstract] [Full Text] [Related]
18. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
19. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
[TBL] [Abstract][Full Text] [Related]
20. The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy.
Castagna L; Bono R; Tringali S; Sapienza G; Santoro A; Indovina A; Tarantino V; Di Noto L; Maggio A; Patti C
Front Med (Lausanne); 2022; 9():1072192. PubMed ID: 36561713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
